This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Feature|Videos|April 30, 2025
BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation
Author(s)Bioduro
How BioDuro is expanding its global CRDMO footprint by improving integrated capabilities and delivering high-quality, end-to-end solutions for drug development and manufacturing
Armin Spura, PhD, CEO of BioDuro, talks about the company’s evolution into a fully integrated contract, research, and development manufacturing organization (CRDMO), offering seamless services across discovery to development and commercialization. Spura discusses recent expansions in commercial-scale API production, peptide scale-up, and high-potency capabilities at the company’s Bengbu, China location.
Watch this video and learn more about:
- What differentiates BioDuro as a high-touch, high-quality CRDMO and how its integrated model streamlines drug development.
- The company’s recent facility expansions in the U.S. and China in drug substance synthesis, peptide production, and more.
- How BioDuro navigates geopolitical and regulatory landscapes while scaling global operations and client-specific solutions.
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.